Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valcyte for chronic lymphocytic leukemia – proof-of-principle antiviral study
2010-021786-78Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valganciclovir in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Medical University of Vienna. Primary endpoint: Relative change in lymphocyte counts. Started Sep 2010; status: completed.
02
Drugs
valganciclovir
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2010-021786-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021786-78.